BofA Cuts West Pharmaceutical (WST) Target Following Model Update and Sector Pressure

West Pharmaceutical Services, Inc. (NYSE:WST) is included among the 13 Best Strong Buy Dividend Stocks to Invest in.

On February 13, BofA lowered its price recommendation on West Pharmaceutical Services, Inc. (NYSE:WST) to $300 from $370. It reiterated a Buy rating on the stock. The firm’s view followed what it described as “a solid finish to the year,” along with FY26 guidance that came in ahead of expectations. The outlook reflected accelerating growth in its non-GLP-1 high-value products segment. After reviewing the company’s earnings and updated guidance, BofA revised its financial model. The firm also applied a lower valuation multiple, pointing to broader group compression across the sector.

A few days later, on February 16, 2026, West Pharmaceutical Services announced that its Board of Directors had declared a regular quarterly dividend of $0.22 per share on its common stock. The dividend will be paid on May 6, 2026, to shareholders on record as of April 29, 2026. This move continued the company’s established pattern of returning capital to shareholders.

On February 17, 2026, the Board took another step in that direction by authorizing a new share repurchase program. The plan allows the company to buy back up to $1 billion of its common stock, reinforcing its commitment to shareholder returns and capital allocation discipline.

West Pharmaceutical Services, Inc. (NYSE:WST) remains a key player in the healthcare supply chain. The company provides specialized solutions that support injectable drug delivery. By working closely with both established pharmaceutical firms and emerging biotech developers, West plays an important role in helping ensure that critical medicines are safely contained and delivered to patients.

While we acknowledge the potential of WST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best NASDAQ Dividend Stocks to Buy Now and 14 Best Low Volatility Dividend Stocks to Invest In

Disclosure: None.